TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16037156

Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum capsules 1.5 g daily for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12739921

Group type: EXPERIMENTAL
Intervention: New teaching method for VAS
Number of subjects: 106

Group type: COMPARATOR
Intervention: Previous teaching method for VAS
Number of subjects: 106
Study: 10687910

Group type: EXPERIMENTAL
Intervention: 1‐mg increments of midazolam at 1‐min intervals
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.1‐mg increments of midazolam without a lock‐out interval
Number of subjects: 32
Study: 8558744

Group type: EXPERIMENTAL
Intervention: rUK 4000 IU/min
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: rUK 2000 IU/min
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: rUK 6000 IU/min
Number of subjects: 213

Group type: COMPARATOR
Intervention: surgery
Number of subjects: 213
Study: 1725892

Group type: EXPERIMENTAL
Intervention: Oral nicardipine (3 x 30 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 25
Study: 6351585

Group type: EXPERIMENTAL
Intervention: Ground lentils
Number of subjects: 6

Group type: COMPARATOR
Intervention: Whole lentils
Number of subjects: 6
Study: 31610637

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body weight via 12 ounces of coffee)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 0
Study: 29624720

Group type: EXPERIMENTAL
Intervention: HOME Plus intervention group (cooking and nutrition education sessions, goal-setting activities, motivational interviewing telephone calls)
Number of subjects: 160
Study: 27618781

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency coagulation of the facet joint capsule
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Percutaneous denervation of the medial dorsal branch
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no radiofrequency lesioning)
Number of subjects: 120
Study: 24092475

Group type: EXPERIMENTAL
Intervention: Multiorgan ultrasonography
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Lung ultrasonography
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Heart ultrasonography
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Vein ultrasonography
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Multiorgan ultrasonography negative for PE
Number of subjects: 357
Study: 22331346

Group type: EXPERIMENTAL
Intervention: Repeated low saturated fat dietary counseling
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1062
Study: 20591628

Group type: EXPERIMENTAL
Intervention: Metformin (MET) 1000 mg/day for 14 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo for 14 weeks
Number of subjects: 56
Study: 17266067

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR), 8-week intervention, 2.5-hour sessions weekly, led by a licensed clinical psychologist.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Waiting-list control group, n = 40.
Number of subjects: 91
Study: 16102151

Group type: EXPERIMENTAL
Intervention: Nurse-led support and education programme (attended 5-6 times over six months)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nurse-led support and education programme (attended fewer times)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 12764515

Group type: EXPERIMENTAL
Intervention: Praziquantel (60 mg/kg per day for three consecutive days)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Oxamniquine (two daily doses of 10 mg/kg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 106
Study: 10600424

Group type: EXPERIMENTAL
Intervention: 200 mg of ascorbic acid supplementation per day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1000 mg of ascorbic acid supplementation per day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8763515

Group type: EXPERIMENTAL
Intervention: Alteplase (100 mg over 3 hours)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 1663571

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol (Oestrogel)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (Premarin)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Micronized oral progesterone
Number of subjects: 63
Study: 7027873

Group type: EXPERIMENTAL
Intervention: Oral bromhexine, 32 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30326960

Group type: EXPERIMENTAL
Intervention: ThrIVe-B intervention plus treatment as usual
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 48
Study: 27209622

Group type: EXPERIMENTAL
Intervention: Total AV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diaphyseal AV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Distal AV
Number of subjects: 40
Study: 24452943

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with optimal mineral-content diet (diet group, 27 subjects)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Antihypertensive treatment without dietary change (control group, 18 subjects)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall antihypertensive treatment
Number of subjects: 45
Study: 22415208

Group type: EXPERIMENTAL
Intervention: FIFA 11+ program
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 20182039

Group type: EXPERIMENTAL
Intervention: Cerebral blood flow (CBF) measurement by PET under baseline conditions
Number of subjects: 27

Group type: COMPARATOR
Intervention: Anti-hypertensive treatment
Number of subjects: 27
Study: 18681100

Group type: EXPERIMENTAL
Intervention: Twice-weekly strength training over 2 years
Number of subjects: 80
Study: 15912037

Group type: EXPERIMENTAL
Intervention: Group III residents (PGY >/= 4) for open repairs
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Group III residents (PGY >/= 4) for laparoscopic repairs
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Group II residents (PGY 3) for laparoscopic repairs
Number of subjects: 1983

Group type: COMPARATOR
Intervention: All groups for laparoscopic repairs
Number of subjects: 1983

Group type: COMPARATOR
Intervention: All groups for both repairs
Number of subjects: 1983
Study: 12420654

Group type: EXPERIMENTAL
Intervention: Interpretive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 0
Study: 10526808

Group type: EXPERIMENTAL
Intervention: Anesthesiology Consultant Report (ACR)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Routine discharge instructions
Number of subjects: 371
Study: 8717556

Group type: EXPERIMENTAL
Intervention: 100mg aspirin daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 1952169

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with postoperative epidural analgesia (GEN‐EPI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: General anesthesia with on‐demand narcotic analgesia (GEN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (40 patients without atherosclerotic vascular disease)
Number of subjects: 80
Study: 6174346

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30256662

Group type: EXPERIMENTAL
Intervention: HMD (head-mounted display)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mobile phone VR
Number of subjects: 44
Study: 27894037

Group type: EXPERIMENTAL
Intervention: Dysregulation profiles
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Internalizing profile
Number of subjects: 433
Study: 24791969

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 μg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline 0.15 ml/kg (Control Group C)
Number of subjects: 100
Study: 23261045

Group type: EXPERIMENTAL
Intervention: High-Dose (HD) trivalent inactivated influenza vaccine (60μg of hemagglutinin per strain)
Number of subjects: 9172

Group type: COMPARATOR
Intervention: Standard Dose (SD) trivalent inactivated influenza vaccine (15μg of hemagglutinin per strain)
Number of subjects: 9172

Group type: EXPERIMENTAL
Intervention: High-Dose (HD) trivalent inactivated influenza vaccine
Number of subjects: 9172

Group type: COMPARATOR
Intervention: Standard Dose (SD) trivalent inactivated influenza vaccine
Number of subjects: 9172
Study: 20880602

Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid therapy (ALA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19436660

Group type: EXPERIMENTAL
Intervention: Methamphetamine use (MU)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Non-married status (combined never married or divorced/separated)
Number of subjects: 82
Study: 16428564

Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single-shot spinal (SSS) technique
Number of subjects: 30
Study: 15146341

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy in the early (prepsychotic) prodromal state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amisulpride treatment in the late prodromal (early psychotic) state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal clinical treatment
Number of subjects: 0
Study: 11244667

Group type: EXPERIMENTAL
Intervention: Fast flush as needed and nonwaste blood sampling
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Fast flush as needed and waste blood sampling
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Fast flush every 4 hours and waste blood sampling
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Fast flush every 4 hours and nonwaste blood sampling
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Insertion sites 3 cm or higher above the radiocarpal joint
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 174
Study: 9165136

Group type: EXPERIMENTAL
Intervention: Continuous radiotherapy (310 patients)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Split-course radiotherapy (191 patients)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Continuous radiotherapy for moderately and well-differentiated tumors
Number of subjects: 501

Group type: COMPARATOR
Intervention: Split-course radiotherapy for moderately and well-differentiated tumors
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Continuous radiotherapy for poorly differentiated tumors
Number of subjects: 501

Group type: COMPARATOR
Intervention: Split-course radiotherapy for poorly differentiated tumors
Number of subjects: 501
Study: 8002537

Group type: EXPERIMENTAL
Intervention: Continuous Negative Airway Pressure (CNAP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous Positive Extrathoracic Pressure (CPEP)
Number of subjects: 8
Study: 2569848

Group type: EXPERIMENTAL
Intervention: Vecuronium bromide (VEC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Succinylcholine (Suc)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Succinylcholine (Suc) infusion
Number of subjects: 40
Study: 4817160

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (25 g) in the morning
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (25 g) in the afternoon
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (non‐apprehensive subjects)
Number of subjects: 13
Study: 31634193

Group type: EXPERIMENTAL
Intervention: Recombinant gp120 protein vaccine (Vax004 clinical trial)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 675
Study: 31264761

Group type: EXPERIMENTAL
Intervention: Achieving HbA1c, cholesterol, and blood pressure targets
Number of subjects: 371

Group type: COMPARATOR
Intervention: Achieving one target
Number of subjects: 371

Group type: COMPARATOR
Intervention: Achieving two targets
Number of subjects: 371

Group type: COMPARATOR
Intervention: Achieving three targets
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: All T2D patients achieving all three targets
Number of subjects: 371
Study: 25978820

Group type: EXPERIMENTAL
Intervention: Personalized drinking feedback (PDF)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Educational information (EDU)
Number of subjects: 325
Study: 23282136

Group type: EXPERIMENTAL
Intervention: Malaria infection
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Ascaris co-infection
Number of subjects: 690
Study: 21527603

Group type: EXPERIMENTAL
Intervention: Cyclic parenteral nutrition (PN) with DEHP exposure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nontreated infants
Number of subjects: 12
Study: 18772101

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogue combined with mifepristone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilatation and evacuation (D&E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues administered by non-invasive routes
Number of subjects: 0
Study: 16581549

Group type: EXPERIMENTAL
Intervention: Succimer treatment
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 780
Study: 14627852

Group type: EXPERIMENTAL
Intervention: Standardized 131I activities
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Disease specific standard values per millilitre of thyroid tissue
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Pre‐therapeutic radioiodine test
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 24 h and 48 h test uptake measurements
Number of subjects: 218
Study: 11077136

Group type: EXPERIMENTAL
Intervention: Antero-lateral paddle position
Number of subjects: 59

Group type: COMPARATOR
Intervention: Antero-posterior paddle position
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Antero-lateral followed by antero-posterior shocks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Antero-posterior followed by antero-lateral shocks
Number of subjects: 59
Study: 8839903

Group type: COMPARATOR
Intervention: CEF (cyclophosphamide 600 mg/sqm i.v., epidoxorubicin 60 mg/sqm i.v. and fluorouracil 600 mg/sqm i.v.)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: DES-CEF (diethylstilbestrol 1 mg orally days 1-3, CEF on day 4)
Number of subjects: 258
Study: 1948120

Group type: EXPERIMENTAL
Intervention: Simultaneous chemotherapy with 25 mg/m2 of 4-epirubicin intravenously for 18 weeks after surgical castration.
Number of subjects: 145

Group type: COMPARATOR
Intervention: Hormonal therapy with surgical castration and long-term administration of flutamide without initial chemotherapy.
Number of subjects: 145
Study: 6842023

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) therapy
Number of subjects: 20
Study: 31960396

Group type: EXPERIMENTAL
Intervention: Aromatherapy (20-min inhalation of essential oil every night for 4 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (20-min inhalation of sweet almond oil every night for 4 weeks)
Number of subjects: 84
Study: 31815509

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: CBT and MI
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: MI-CBT
Number of subjects: 85
Study: 30115084

Group type: EXPERIMENTAL
Intervention: Reducing portion sizes of foods available in cafeterias by at least 10% from targeted categories (main meals, sides, desserts, cakes).
Number of subjects: 6

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 6
Study: 27012778

Group type: EXPERIMENTAL
Intervention: Proton-Pump Inhibitors (PPIs)
Number of subjects: 3752

Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 3752

Group type: COMPARATOR
Intervention: High-dose aspirin
Number of subjects: 3752
Study: 25089271

Group type: EXPERIMENTAL
Intervention: Adhesive glue
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional suturing
Number of subjects: 102
Study: 22739394

Group type: EXPERIMENTAL
Intervention: Nevirapine (50 mg), Stavudine (6 mg), Lamivudine (30 mg) in fixed dose combination tablet (Triomune Baby)
Number of subjects: 16
Study: 19469798

Group type: EXPERIMENTAL
Intervention: Potassium-titanyl-phosphate (KTP) laser
Number of subjects: 14

Group type: COMPARATOR
Intervention: Electrodesiccation
Number of subjects: 14
Study: 17855332

Group type: EXPERIMENTAL
Intervention: Brief counselling intervention (N = 442)
Number of subjects: 906

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 906
Study: 14678081

Group type: COMPARATOR
Intervention: SR 49059 (0, 25, 75, or 200 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vasopressin (10 pmol/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oxytocin (50 pmol/kg)
Number of subjects: 16
Study: 12224974

Group type: EXPERIMENTAL
Intervention: Intracisional clindamycin
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Buffered lidocaine with epinephrine without clindamycin (Control)
Number of subjects: 1030
Study: 9675622

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg three times a day with 125 mg MK-0591 twice a day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ibuprofen 600 mg three times a day with placebo for MK-0591
Number of subjects: 12

Group type: COMPARATOR
Intervention: MK-0591 125 mg twice a day with placebo for ibuprofen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined treatment (Ibuprofen and MK-0591)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9972889

Group type: EXPERIMENTAL
Intervention: Common carotid-subclavian artery bypass (CSB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subclavian-carotid transposition (SCT)
Number of subjects: 40
Study: 2651767

Group type: EXPERIMENTAL
Intervention: DST with cyclosporin A (group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: DST alone (group II)
Number of subjects: 50
Study: 318897

Group type: EXPERIMENTAL
Intervention: Acupuncture with electrically stimulated needles
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acupuncture with needles inserted to avoid recognized acupuncture points
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control session (without needles)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acupuncture on the epigastrium
Number of subjects: 12
Study: 31560794

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.3% triclosan + 2.0% PVM/MA copolymer + 1450 ppm fluoride (Test)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Toothpaste containing 1450 ppm fluoride (Control)
Number of subjects: 88
Study: 31276981

Group type: EXPERIMENTAL
Intervention: ET + Bev
Number of subjects: 749

Group type: COMPARATOR
Intervention: ET
Number of subjects: 749
Study: 29192318

Group type: EXPERIMENTAL
Intervention: 2-talker speech masker
Number of subjects: 84

Group type: COMPARATOR
Intervention: speech-spectrum noise
Number of subjects: 84
Study: 25451581

Group type: EXPERIMENTAL
Intervention: Parenting intervention for problem-eaters
Number of subjects: 201

Group type: COMPARATOR
Intervention: Waitlist control for problem-eaters
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Parent-reported meal length concern
Number of subjects: 201
Study: 24238679

Group type: EXPERIMENTAL
Intervention: Video intervention group (5 minutes from the Play Nicely program)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Handout group ('Pulling the Plug on TV Violence')
Number of subjects: 312

Group type: COMPARATOR
Intervention: Primary control group (standard primary care)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Alternative control group (program about obesity prevention)
Number of subjects: 312
Study: 21664510

Group type: EXPERIMENTAL
Intervention: Theory-based Interactive Postpartum Sexual Health Education Program
Number of subjects: 250

Group type: COMPARATOR
Intervention: Pamphlet only
Number of subjects: 250

Group type: COMPARATOR
Intervention: Routine education
Number of subjects: 250
Study: 19801228

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite (NaOCl)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 2% chlorhexidine (CHX) gel
Number of subjects: 54
Study: 16682611

Group type: EXPERIMENTAL
Intervention: Transdermal GTN (5 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 15642960

Group type: EXPERIMENTAL
Intervention: Combination therapy with sulfadoxine-pyrimethamine plus artesunate
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Counseling about what to do if a patient vomits
Number of subjects: 453
Study: 11320018

Group type: EXPERIMENTAL
Intervention: Initial medication (n = 307)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Initial surgery (trabeculectomy, n = 300)
Number of subjects: 607
Study: 9263611

Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day, T.D.D.) with 500 mg/day of calcium
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo with 500 mg/day of calcium
Number of subjects: 39
Study: 8426770

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (DTaP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine (DTwP)
Number of subjects: 100
Study: 3723990

Group type: EXPERIMENTAL
Intervention: Doxorubicin (15 mg/m2, 4 times per 48 h)
Number of subjects: 0
Study: 29232172

Group type: EXPERIMENTAL
Intervention: PEGPH20 plus nab‐paclitaxel/gemcitabine (PAG)
Number of subjects: 279

Group type: COMPARATOR
Intervention: nab‐paclitaxel/gemcitabine (AG)
Number of subjects: 279
Study: 27460675

Group type: EXPERIMENTAL
Intervention: 6-month multi-component behavioural change intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 156
Study: 24621155

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (OXS regimen)
Number of subjects: 94

Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 94
Study: 22499961

Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon pump (n=359, 15.3% of high-risk patients)
Number of subjects: 2348

Group type: COMPARATOR
Intervention: No preoperative intra-aortic balloon pump (n=1989, 84.7% of high-risk patients)
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon pump
Number of subjects: 2348
Study: 21077043

Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP) treatment (CVVH)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No continuous blood purification (no CVVH)
Number of subjects: 63